MI-ONESTREAM-SOFTWARE
16.2.2021 12:02:06 CET | Business Wire | Press release
OneStream Software , a leader in corporate performance management (CPM) solutions for mid-sized to very large enterprises, and PwC UK announced today they have entered into a strategic alliance for the UK market. The partnership will leverage PwC’s expertise as a leading business and technology consulting services provider and OneStream’s unified and cloud-based CPM software to support activities ranging from project delivery to marketing and strategic business collaboration.
“The UK is an important market for OneStream Software and we are excited to welcome PwC UK to our partner ecosystem,” said Stephanie Cramp, SVP of Global Alliances at OneStream Software. “We look forward to working with PwC to help organizations in the UK and across the EMEA region conquer complexity and transform their finance processes by leveraging our intelligent finance platform to replace multiple legacy applications, as well as point solutions and spreadsheets.”
As part of the partnership, PwC UK will further develop its OneStream implementation practice to serve joint customers in the UK but also across the EMEA region. PwC UK will also leverage their industry and domain expertise to create compelling industry specific solutions with OneStream for clients across the market.
“We believe that a combination of OneStream’s unified corporate performance management solution alongside PwC’s industry, functional and implementation expertise can be a real enabler to making a step change in process efficiency, cost-effective growth, and improved decision-making for our clients. We are already seeing the benefits of this in a number of our clients and look forward to our continued collaboration with OneStream going forward,” stated Dan Bell, Partner, Enterprise Performance Management Lead, PwC UK.
“We are thrilled about our alliance with PwC UK, specifically due to the domain expertise and best practices this will bring to OneStream customers in this important market,” said Matt Rodgers, Senior Vice President and EMEA Managing Director at OneStream Software. “This partnership will enable OneStream to extend its delivery capabilities in EMEA and supports our mission of delivering 100% customer success worldwide.”
For more information on the PwC UK-OneStream alliance, visit: www.onestreamsoftware.com/about/onestream-partners and https://www.pwc.co.uk/press-room.html .
About OneStream Software
OneStream Software provides a market-leading intelligent finance platform that reduces the complexity of financial operations. OneStream unleashes the power of finance by unifying corporate performance management (CPM) processes such as planning, financial close & consolidation, reporting and analytics through a single, extensible solution. We empower the enterprise with financial and operational insights to support faster and more informed decision-making. All in a cloud platform designed to continually evolve and scale with your organization.
OneStream is an independent software company backed by private equity investor KKR. With over 600 customers, 200 partners and over 700 employees our primary mission is to deliver 100% customer success.
About PwC UK
At PwC, our purpose is to build trust in society and solve important problems
PwC is a network of over 284,000 professionals around the world, of which about 6,400 in Italy, committed to guaranteeing quality in auditing, technological, strategic, legal and tax consulting services for businesses.
Thanks to our sector expertise, we provide complete and tailor-made solutions as well as a wide range of services in an integrated and multidisciplinary way. Our strength is to be able to combine our knowledge of local markets with a global organization.
We are one of the largest professional services networks in the world, but size is only part of who we are; creating value for our customers, our people and the society in which we live and work is at the heart of PwC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005133/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom